Initially developed for Parkinson’s disease, CEP-1347 is a pharmacological inhibitor of MDMX that has also been shown to suppress the expression of MDM4 in retinoblastoma cell lines [147,190]. This evidence concerns the gene MDM4 and retinoblastoma.